Home
Search
Search Results
Previously Searched
3146 results found
Expand All
Apply All
3146 results found

Mexico, China, and the future of biotech trade
Good Day BIO Newsletter  •  May 14, 2021
A recap of this week’s hearings on the Biden administration’s trade policy agenda, words of wisdom from Dr. Michelle on how to address vaccine hesitancy among communities of color, and a lot of news. (960 words, 4 minutes, 40 seconds)
Read More

BIO Joins Letter Supporting Endless Frontier Act
Agriculture & Environment  •  Letters, Testimony & Comments  •  May 13, 2021
The undersigned trade associations and private sector organizations write to express our strong support for the Endless Frontier Act, sponsored by Senate Majority Chuck Schumer (D-NY) and Senator Todd Young (R-IN), which would provide much needed, and long overdue, investment in technology, entrepreneurship, science, research and development, and will promote the long-term, global economic competitiveness of the United States. We are encouraged by this bold and visionary bipartisan effort to ensure the U.S. can out-compete our foreign competitors, especially China. We encourage Congress to make passage of this bill a top priority as we move into a period of economic recovery and job growth post-COVID.
Read More

Who develops medicines?
Good Day BIO Newsletter  •  May 13, 2021
We have details on a new study about who really funds FDA-approved medicines, and a bill making its way through the Senate that would boost R&D and the bioeconomy. We’re also watching a House Ways & Means Committee hearing with USTR; we’ll have more on that tomorrow. (716 words, 3 minutes, 34 seconds)
Read More

BIO Joins Letter to President Biden Urging the Need for U.S. Leadership in Global Vaccinations
Vaccines  •  Letters, Testimony & Comments  •  May 12, 2021
Dr. Michelle McMurry-Heath, along with a group of business and policy leaders, sends an open letter to President Biden urging him "to demonstrate decisive U.S. leadership" to combat COVID-19 in Latin America, Europe, Asia, and Africa. 
Read More

Price controls, patent waivers, and Mexico's biotech policies
Good Day BIO Newsletter  •  May 12, 2021
Ahead of congressional hearings today and tomorrow on the Biden administration’s trade policy agenda, we’re unpacking two critical global trade issues: IP protections for COVID-19 vaccines and Mexico’s response to gene-edited agricultural products, specifically corn. (892 words, 4 minutes, 27 seconds)
Read More

Pfizer-BioNTech vaccine authorized for teens ages 12-15
Good Day BIO Newsletter  •  May 11, 2021
Today’s all about the kids. The FDA authorized the use of Pfizer’s vaccine in younger teens, and Amyris announced a new partnership to help families and babies in need stay safe during the pandemic. Here’s what you need to know—plus how you can help. (698 words, 3 minutes, 29 seconds)
Read More

BIO Extends Agreement with Avantor
Press Release  •  May 10, 2021
Today, the Biotechnology Innovation Organization (BIO) announced an extension through June 2029 to its established agreement with Avantor. Through this agreement, members across North America have access to a broad portfolio of products and services—including laboratory supplies, chemicals, life sciences tools, equipment, chromatography, safety supplies, cleanroom products, and more. Avantor is a preferred supplier partner of BIO Business Solutions®. “BIO is extremely pleased to extend our 23-year long program with Avantor, which has proven itself with consistent growth. Avantor’s exceptional service provides value critical for the thousands of life science companies participating in the BIO Business Solutions® program,” said BIO President and CEO Dr. Michelle McMurry-Heath. “As a global supplier of discovery-to-delivery solutions for the entire biotech ecosystem, Avantor’s services allow innovators to preserve capital and focus on the science that will improve and save lives.” The extended agreement aggregates the purchasing power of BIO’s member and affiliate member companies and drives significant value.    “For more than 23 years, Avantor has been proud to collaborate with BIO Business Solutions and we’re pleased to play a critical role in helping members develop scientific breakthroughs,” said Frederic Vanderhaegen, Executive Vice President, Americas and Europe. “Our broad portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve and provides scientists with all they need to create life-changing treatments for patients. We offer everything from high purity products to equipment and instrumentation to services optimizing scientific workflows. Looking ahead, we are excited about what we can accomplish together.”    To learn more about the benefits of BIO…
Read More
BIO Avantor Agreement

Good trouble for good medicine
Good Day BIO Newsletter  •  May 10, 2021
Starting a new week with a discussion on why diversity has been lacking in clinical trials—and what the industry can do about it. Listen to the latest episode of the I AM BIO Podcast or keep reading. We also have sweet news for plastic pollution and news on a historic nominee at USDA. (712 words, 3 minutes, 33 seconds)
Read More

BIOcares Grant Reviewer Questions
html legend { display: block; font-size: 16px; font-family: "NunitoSans",sans-serif; }
Read More

BIOcares Grant Application Information
Biotechnology Innovation Organization (BIO) is proud announce the launch of the BIOcares Grant Program. As longtime supporters of the patient advocacy community, we are launching this program to assist in non-profit advocacy partners’ efforts to rebuilt, in light of the COVID-19 pandemic and economic fallout. This pooled grant program is funded by over a dozen BIO member companies, all of whom abide by BIO's Guiding Principles for Interaction with Patient Advocacy Organizations.
Read More